2024 Patient Experience Survey

GLCC Who We Are
Understanding lung cancer patients’ experiences

Insights from the Global Lung Cancer Coalition’s 2024 global patient experience survey

October 2024

Introduction

For the last five years, the Global Lung Cancer Coalition (GLCC) has run an annual global patient experience survey, gathering a wealth of useful data and insights on experiences of diagnosis, treatment, and care. We at the GLCC want to understand patients’ experiences of lung cancer and the barriers and challenges they face to inform our global and national campaigning priorities, and we conduct this survey yearly to ensure our ongoing activities and advocacy are reflective of current patient experiences, needs, and preferences.

This report sets out the global findings from our fourth annual global survey, which ran from 28 March 2024 to 14 May 2024 and received 905 responses from patients across 18 countries.

We are grateful to all the patients who took the time to share their experiences via the survey. We hope the findings will be useful to policymakers in their planning, as well as to campaigners advocating for lung cancer patients’ needs.

Key findings & common themes

As stated in our patient charter, the GLCC believes that every patient has the right to have access to quality health care; informed self-determination; physical and mental integrity; and confidentiality and privacy, and to be treated with dignity and respect.

While each patient’s experience and preferences during their lung cancer journey are different, there are some common themes across varying geographies and health systems.

This year’s patient experience survey highlighted some encouraging trends including improved involvement score in treatment and care decisions (when compared to the 2023 results) and good support for patients who either chose not to pursue or have no treatment options available.

However, it was also clear from the survey results that more needs to be done to ensure patients get the information they need at the time that it is most useful to them. This is true across the patient journey, including for biomarker testing – where there is still significant confusion amongst patients despite relatively high levels of access to testing.

Our Global Report into the findings from our 2024 survey can viewed and downloaded as a Word document or in pdf format here:

Global Report WORD document

Global Report pdf 

The following national infographics can be downloaded in pdf format:

Argentina

Australia

Bulgaria

Canada

Denmark 

Greece

Ireland

Israel

Italy

Japan

Mexico

Netherlands

Portugal

South Africa

Spain 

Taiwan

UK 

USA

 

 

 

 

global
RESEARCH - The State of Global Lung Cancer Research - 2020 data now published / NEWS - global COVID-19 updates